Inmune Bio, Inc. (INMB) Stock Price & Analysis

Inmune Bio, Inc. (INMB) rose 7.49% to USD 2.44 as of September 8, 2026 at 10:12 UTC, according to Nexqual real-time market data.

INMB last closed at USD 2.44; the session ranged USD 2.22–2.45 on volume of 323,961 shares. Market capitalization is —, with a 52-week range of USD 1.09–2.5 (NCM). Source: Nexqual, September 8, 2026 at 10:12 UTC.

Key Statistics (as of September 8, 2026 at 10:12 UTC)

Technical Analysis (INMB)

Nexqual's technical model rates INMB "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 10:12 UTC.

From Inmune Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• Terms of the GOSH license include an upfront payment of £250,000 (approximately $0.3 million) which the Company paid during 2025 and a single milestone payment of up to £6,000,000 (approximately $8.1 million at December 31, 2025) due on the first to occur marketing authorization to be granted by the FDA, EMA or MHRA.
• Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology.   Lead Program : CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom, our proprietary, pooled, human umbilical cord-derived mesenchymal stromal cell platform.
• The following table summarizes current IP covering our DN-TNF platform technology:     INB-16 / INKmune (Oncology)   INKmune is a replication-incompetent derivative of our proprietary INB-16 cell line.

Partnerships

• All other provisions in the INKmune License Agreement shall continue in full force and effect.   12     University of Pittsburg License Agreement   On October 3, 2017, the Company entered into an Assignment and Assumption Agreement with Immune Ventures related to intellectual property licensed from the University of Pittsburgh.
• During June 2021, the Company entered into the First Amendment to License Agreement with Xencor.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:12 UTC. This page is informational and not investment advice.